Keightley Amen
Articles by Keightley Amen
Research has shown that weight gain and obesity can be associated with an increased risk of developing breast cancer.
Some research has shown that patients with certain autoimmune diseases have a lower risk of breast cancer.
“CTCs contribute to the metastatic cascade and represent an independent survival predictor in breast cancer."
Research has shown that women with breast cancer who live in socioeconomically disadvantaged areas have poorer outcomes.
Breast cancer that is hormone receptor (HR)-positive tends to be diagnosed early, when it is highly treatable.
The new research was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Younger patients with breast cancer tend to have a poorer prognosis and higher rates of recurrence.
Many low-income areas of the world still experience poor outcomes and lack information to guide improvements.
A study examined the effectiveness of adding pyrotinib, a new tyrosine kinase inhibitor (TKI).
Identification of human epidermal growth factor receptor 2 status is important in breast cancer diagnosis.
Much research has examined the effects of body mass index (BMI) on breast cancer risk and outcomes.
Triple-negative breast cancer tends to have relatively poor long-term outcomes compared to other subtypes of breast cancer.
According to data presented at ASCO 2022, Afib is associated with worse outcomes from breast cancer.
In developed countries, breast cancer treatment has become much more effective due to advances in molecular subtyping.
A study presented at ASCO 2022 provided data on a new method using MRI and 3D printing to create breast surgical guides.
Biomarker assessment is a very useful tool often used to make treatment decisions.
The authors described their experiences with prepectoral implant placement.
A retrospective review identified female patients with HER2-positive breast cancer who started therapy with TDM1 or TDXd.
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.